Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are as follows:
In participants with primary Type I or II achalasia, following a single 5-mg dose of
olinciguat (IW-1701),
- To assess the safety and tolerability
- To determine the effects on measures of esophageal function by high-resolution impedance
manometry (HRIM)
- To determine the pharmacokinetic (PK) parameters
Phase:
Phase 2
Details
Lead Sponsor:
Cyclerion Therapeutics Ironwood Pharmaceuticals, Inc.